Arthrosis Hip
Conditions
Interventions
Group I: 3 ml hyaluronic acid and 2 ml lidocaine
Group II: 2 ml corticosteroids and 3 ml lidocaine
Sponsors
Maatschap Orthopedie, Medisch Centrum Leeuwarden
Eligibility
Inclusion criteria
Inclusion criteria: 1. Age 18 years or older 2. Symptomatic coxarthritis 3. Baseline hip pain VAS score of 15 mm or more 4. Signed informed consent
Exclusion criteria
Exclusion criteria: 1. Ipsilateral gonarthritis 2. Clinical significant neurologic or vascular disease 3. Previous intra-articular injections in the affected hip 4. Osteonecrosis or osteomyelitis of the affected hip 5. Rheumatoid arthritis or other inflammatory arthrides 6. Previous surgical procedures of the hip 7. Active or suspected infection in or around the hip 8. Limitation to give an intra-articular injection in the affected hip 9. Current treatement with corticisteroids for another disease 10. Serious liver or kidney failure 11. An alcohol or drug addiction 12. Pregnancy or breastfeeding 13. Contraindications to components of Fermatron, Depomedrol or lidocaine
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Differences in pain reduction between patients with osteoarthritis of the hip treated with intra-articular injections with Fermathron S (hyaluronic acid) and patients treated with corticosteroids (Depomedrol). | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Differences in function and radiological changes between the group treated with Fermathron S and the group treated with Depomedrol. 2. Safety of Fermathron S in patients with osteoarhritis of the hip. 3. Differences in paracetamol consumption between the group treated with Fermathron S and the group treated with Depomedrol. | — |
Contacts
Public ContactP.C. Rijk
Henri Dunantweg 2 8934 AD Leeuwarden The Netherlands
Outcome results
None listed